Quality of life ‐ not measured · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not reported · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · health problem or population
Summary of findings table ‐ GABA‐analogues showed no clear difference in risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
FEV1 · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Z score FVC · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
HRCT score · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Weight (z score) · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Number of positive P aeruginosa isolates · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Number or proportion of hospitalisations · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Hospital costs · infants and children with pulmonary exacerbations in cystic fibrosis
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
Infliximab probably leads to lower clinical relapse (at 30‐32 weeks, CDAI > 150) compared with placebo (moderate certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 32 weeks, less than 70 points in CDAI… compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review